Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed I suspect not. Although if there is it will need to be PR'ed in about an hour.
I note that the slide presentation is dated February 2017.
The Corporate presentation is still from 2016 and the latest presentation available on anavex.com is from CTAD 2016.
Is there anything new in that Asia Bio presentation...?
Quiet place this board and hope you are right. With financing and a potential pivot-able trial about to start we may get some of the desired action - at long last!
Yes I think Missling is playing an admirable, but risky game if Rett does not work out well. Guess he must be quite confident, if indeed going it alone using the shelf with minimum dilution is his game plan.
Based upon slides 18 and onwards: ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology, it seems A2-73 has pathological benefits rather than being decease modifying.
An impressive read the way the Anavex accomplishments and events are laid out in that report!
http://eithealth.eu/partners/biom-biotech-cluster-development-gmbh/
This is the c/o address org. Maybe a cost effective way for Anavex to build out their R&D capability.
LOL, excellent analogy and how true to real world it is
I read it opposite that A2-73 is further along than A3-71 in Parkinson's. Phase 2 seems to be denoted by green arrows. So a longer smudge of green for A2-73 Parkinson's, I read as closer to entering Phase 2. But then again not sure how much can be read into the length of the green bit of the arrows...
A guess could be that a MOC order won't have the possibility of starting a run and sort of put a lid on subsequent rapid price increases.
Why did Biotech in general gap up yesterday. I don't know..
Prospectus, LPC agreement and proxy vote - how I understand it, so please do comment and correct.
This is the latest SEC filing regarding the LPC agreement.
$100,000,000 of Shares of Common Stock and Warrants
I had forgotten that the prospectus is for a $100M facility, but still based on maximum 6,754,609 Shares of Common Stock.
The prospectus talks about a primary and secondary offering, where the existing LPC agreement constitutes a secondary offering of up to $50M.
So the other up to $50M of the primary offering can yet become effective and not necessarily involving LPC, ie. could be sold to anyone offering better terms and the prospectus potentially being amended from time to time.
About 4M shares have been sold to LPC, so far as we can tell, and raised some $15M.
That means roughly 2.5M shares that can still be sold per the prospectus.
Thank you for your reminder. Keep forgetting how unsophisticated I am. Keep up the good work.
No, same old 2015 LPC agreement and $50,000,000, of which about 1/3 has already been taken. Though I am not quite sure why it has to be ratified again by share holders.
Probably a timely find of a mistake.
Oh and change the "Is the study currently looking for suitable participants?" field to All, instead of Recruiting.
Use the Advanced Search tab, then only type Anavex in the Keyword field. Brings up our phase 2 part A and B trials.
Interesting, on my screen the trading session ended with:
22:00:00 5,67 19131 1799 NDRG NDRG 6
19131 is volume of that last trade.
I am in Europe, hence time stamp.
I am keeping an eye here, but so far no new registration: Australian Clinical Trials
Btw. Enough cash to include the LPC facility, which despite all the previous criticism seems be cheap funding.
I was thinking about this interview with Missling (from SEC filing):
Yep, and from everything we've heard from Missling it will not be until the marketing/commercialisation stage that we will see partnership with BP.
To my mind; "Complement current pipeline through in-licensing - ongoing", means Anavex extending their own pipeline by licensing in?
Agree, the most logical outcome is buy-out or solid licensing partnership. I am hopeful and believe that Missling genuinely aim to optimise share holder value.
Can't help being cynical - Still hanging on to the amyloid hypothesis, only sell more of it to a younger population for much longer. Money talks.
Wouldn't it be great to see Anavex fight on through all the headwinds to beat the odds and change this old game for the good.
Sadly, I think you are completely correct.
We see that same attitude in regards to research and long standing empirical knowledge that the food we eat and our life-style in general have profound effects on health. But there is no corporate profits in educating people in healthy living, much more profitable to prescribe medication for symptom management for as longs as possible to as many as possible.
It would be good if Trump could clear that swamp, but will he and could he...
Of course despite life-style changes there will still be deceases for Biotech/Pharma sector to tackle, some of which Anavex may have a good chance of addressing.
Yes I would think Anavex could extend the protection into Alzheimer's and other indications based on showing utility.
The A2-73 composition of matter is protected in this case for cancer. Since Anavex have disclosed other indications, such as Alzheimer's based on the exact same molecule, I would think that preclude others from patenting this particular molecule in any disclosed indication.
It may be possible to improve on A2-73 in novel and non-obvious ways, but it seems to me that the A2-73 patent in the cancer indication offers decent protection for Anavex.
While only the claims, if granted, will provide patent protection, the rest i believe would classify as public disclosure. That would have the effect that no one can later claim same.
Do you have a link for that story, please?
"Celgene Corporation (CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex®)."
http://finance.yahoo.com/news/celgene-announces-positive-results-phase-123000513.html?soc_src=social-sh&soc_trk=ma
Guess more incentive for Biogen to partner with Anavex if successful in testing A2-73.
On a quick look you seem to have taken the worst case of the error bars from each of the data points (for all patients) as published by Anavex for the 57 week CTAD update.
You introduce additional error since we do not have the numbers in tabular form. The figures are hard to read accurately off the graph, say +/- .5 of a point.
Finally you have ignored considering the strong responder data on the CTAD slide no 30.
As far as I know, no such strong responders have been reported in any other AD trial so far.
The strong responders plus the upturn at 57 weeks is what interest me most when taken alongside the positive correlation of the other measures and 'unexpected therapeutic effects'.
We also know that dose were not optimised for the phase 2b trial and that there is evidence of correlation between does and effect.
As always we won't be certain of success until we see the results of the planned P2/3 trial.
Just came across this article with Missling quoted on the Cures Act.
Not to mention AF and JF who put me on to a good investment
Agree with that Raja.
I follow a fairly straight forward strategy to biotech investing, but it requires willingness and effort to do DD, as well as some discipline.
a) I research and at least try to understand the science
b) I examine pps history and the news events that drove price as well SEC filings and financials e.g. how much cash is available / possible dilution
c) Jump on conf calls to hear and feel the sincerity and enthusiasm of the CEO and senior staff. Take note of the Q&A sessions
d) Many biotechs fail, so I aim to keep a portfolio of a least two handfuls of stocks. I make sure my DD selects those firms with BIG potential for returns and accept several will fail. The simple notion here is that the few that win big will more than offsets the losses. I never short or use derivatives and so I know exactly how much I could and am prepared to loose
e) I try hard not to be super overweight in one stock (AVXL is breaking my rule a bit)
f) If I later learn I have misunderstood a stock's potential and it seems downhill all the way, I get rid of it.
g) Meanwhile, I am fine with the expected huge volatility of biotech. So I never use automated stops - sorry Plato7 for being a bit unsophisticated here.
h) When a stock goes high on no apparent news, I may swing trade a bit to reduce cost of the position
i) Likewise, when it goes really well I do cover my cost. I find this a hard discipline, especially with really good stock like AVXL, but longer term I believe in the statistics and try to stick to what I have learned from experience
j) When I decide to buy and sell, I use a little TA to at least not time it completely silly: Price movement, Volume, SMA and Chakin Oscillator. The latter I have found quite a reliable indicator crossing zero down for selling and zero up for buying, but always viewed in combination with the aforementioned data points.
I think that's about it, except to say the research DD is where most of my time/effort goes in before buying.
I completely understand and accept there are many and successful styles of playing the markets, including TA ,day and swing trading.
Interested in hearing the approach other folks take especially to Biotech.
GLTA
To me TA is a bit like Financial Astrology.
As a long term investor, to me it sounds sensible to look at TA to understand immediate past and current trading action. I use some TA mostly around buy and sell trading decisions in an effort not to jump in or out at a much less than optimal time.
Sometimes even I get it right
With the rest of the LPC funding of some $35M available, Anavex may have enough helped by grants.
I am all in!
Table 2 in the article describes a 3 month test point to determine next step in a cholinesterase inhibitor treatment regimen. One could suspect that beyond the 57 week point, where we now have some encouraging A2-73, there is otherwise only decline.